ARRY - Array BioPharma Inc.
| Previous Close | 14.21 |
| Open | 14.10 |
| Bid | 13.85 x 2200 |
| Ask | 14.22 x 900 |
| Day's Range | 13.77 - 14.25 |
| 52 Week Range | 8.50 - 20.21 |
| Volume | 2,693,849 |
| Avg. Volume | 2,567,565 |
| Market Cap | 2.97B |
| Beta | 1.99 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.67 |
| Earnings Date | Oct 29, 2018 - Nov 2, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 23.57 |
Market Realist•yesterdayArray BioPharma Posted Net Loss of $52.4 Million in Q4
On August 14, Array BioPharma (ARRY) announced its fourth quarter and full fiscal 2018 results for the period ended June 30, 2018. The adjusted EPS (earnings per share) for the fourth quarter came in at -$0.17, exceeding analysts’ estimate of -$0.21. Net loss in the fourth quarter of fiscal 2018 was $52.4 million as compared to $29.6 million losses reported in the fourth quarter of fiscal 2017.
Market Realist•yesterdayArray BioPharma Missed Sales Estimates for Q4 2018
Array BioPharma (ARRY) reported its Q4 2018 and fiscal 2018 earnings results August 14. Its sales rose by ~4.9% YoY (year-over-year) to $35.4 million, missing analysts’ estimate of $38.7 million. The rise was mainly due to earned milestones, new and expanded collaborations, and an increase in expense reimbursements related to the Beacon CRC trial. Pierre Fabre, a French pharmaceutical company, has an agreement with Array Biopharma to fund 40% of the cost of the Beacon CRC trial.
Market Realist•yesterdayWhat Analysts Recommend for Array BioPharma Stock
Array BioPharma (ARRY) announced its fourth-quarter and full fiscal 2018 results on August 14. That day, ARRY stock registered a decline of ~2.6% and fell further the following day. The decline in stock prices was triggered by the negative investor sentiments due to the Array BioPharma’s fourth-quarter results falling short of estimates. In this article, we’ll look at analysts’ latest recommendations and target prices on ARRY stock over the next 12 months.
- ACCESSWIRE•yesterday
Today's Research Reports on Trending Tickers: Array BioPharma and AVEO Pharmaceuticals
NEW YORK, NY / ACCESSWIRE / August 17, 2018 / U.S. markets bounced back on Thursday after Walmart and Cisco reported upbeat quarterly earnings. The Dow Jones Industrial Average jumped 1.58 percent to close ...
- Thomson Reuters StreetEvents•4 days ago
Edited Transcript of ARRY earnings conference call or presentation 14-Aug-18 1:00pm GMT
Q4 2018 Array Biopharma Inc Earnings Call
Motley Fool•4 days agoArray BioPharma Inc. (ARRY) Q4 2018 Earnings Conference Call Transcript
ARRY earnings call for the period ending June 30, 2018.
- Zacks•4 days ago
Array BioPharma (ARRY) Reports Q4 Loss, Misses Revenue Estimates
Array BioPharma (ARRY) delivered earnings and revenue surprises of 0.00% and -3.11%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
- Associated Press•4 days ago
Array BioPharma: Fiscal 4Q Earnings Snapshot
The Boulder, Colorado-based company said it had a loss of 25 cents per share. Losses, adjusted for non-recurring costs, were 24 cents per share. The results matched Wall Street expectations. The average ...
- PR Newswire•4 days ago
Array BioPharma Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2018
-- FDA approved BRAFTOVI™ (encorafenib) in combination with MEKTOVI® (binimetinib) for advanced BRAF-mutant melanoma -- -- BRAFTOVI + MEKTOVI received positive CHMP opinion for advanced BRAF-mutant melanoma ...
- ACCESSWIRE•4 days ago
Array BioPharma Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / August 14, 2018 / Array BioPharma Inc. (NASDAQ: ARRY ) will be discussing their earnings results in their Q4 Earnings Call to be held on August 14, 2018 at 9:00 AM Eastern Time. ...
- PR Newswire•8 days ago
Array BioPharma Names Carrie S. Cox Chairman of its Board of Directors
BOULDER, Colo., Aug. 10, 2018 /PRNewswire/ -- Array BioPharma Inc. (ARRY) today announced that Carrie S. Cox has been named Chairman of its Board of Directors, effective immediately. Ms. Cox has been appointed to the Audit and Corporate Governance Committees of the Board. Kyle Lefkoff, General Partner of Boulder Ventures Ltd., who has served as Chairman of Array's Board since its inception, has stepped down as Chairman and will continue to serve as a director.
Markit•9 days agoSee what the IHS Markit Score report has to say about Array Biopharma Inc.
The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising.
- PR Newswire•11 days ago
Array BioPharma to Report Financial Results for the Fourth Quarter and Full Year of Fiscal 2018 on August 14, 2018
BOULDER, Colo. , Aug. 7, 2018 /PRNewswire/ -- Array BioPharma Inc. (Nasdaq: ARRY) will report financial results for the fourth quarter and full year of fiscal 2018 and hold a conference call to discuss ...
- PR Newswire•11 days ago
Array BioPharma Receives FDA Breakthrough Therapy Designation for BRAFTOVI™ in combination with MEKTOVI® and cetuximab for BRAFV600E-mutant Metastatic Colorectal Cancer
- Designation based on Phase 3 BEACON CRC safety lead-in data - BOULDER, Colo. , Aug. 7, 2018 /PRNewswire/ -- Array BioPharma Inc. (NASDAQ: ARRY) today announced it has received Breakthrough Therapy Designation ...
- PR Newswire•22 days ago
BRAFTOVI™ (encorafenib) + MEKTOVI® (binimetinib) Receives Positive CHMP Opinion for Advanced BRAF-mutant Melanoma
- Positive CHMP opinion is based on Phase 3 COLUMBUS trial which demonstrated nearly 15 months median progression-free survival and over 30 months median overall survival - - U.S. FDA recently approved ...
- GlobeNewswire•22 days ago
Market Trends Toward New Normal in Egalet, PPG Industries, Synergy Pharmaceuticals, Equity Residential, Array BioPharma, and Holly Energy Partners — Emerging Consolidated Expectations, Analyst Ratings
NEW YORK, July 27, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Egalet ...
- Zacks•last month
Biotech Stock Roundup: AMGN Resubmits Evenity BLA, Advaxis Soars, Regulatory Updates
It has been a pretty ho-hum week for the biotech sector with a few regulatory updates. Amgen resubmits BLA for osteoporosis drug and Advaxis surges on positive news from FDA.
- ACCESSWIRE•last month
Wired News - NCCN Recommends BRAFTOVI with MEKTOVI as Category 1 Treatment Option for BRAF-Mutant Melanoma
LONDON, UK / ACCESSWIRE / July 17, 2018 / If you want access to our free research report on Array BioPharma Inc. (NASDAQ: ARRY), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=ARRY as the Company's latest news hit the wire. On July 13, 2018, the Company, which is a fully-integrated, biopharmaceutical Company, declared that the National Comprehensive Cancer Network (NCCN) has revised the Clinical Practice Guidelines in Oncology for Melanoma. The new guidelines make BRAFTOVI™ in combination with MEKTOVI® a Category 1 first-line and second-line treatment option for patients suffering with BRAFV600E, or BRAFV600K-mutant metastatic, or unresectable melanoma.
Markit•last monthSee what the IHS Markit Score report has to say about Array Biopharma Inc.
The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Over the last one-month, outflows of investor capital in ETFs holding ARRY totaled $1.26 billion.
- PR Newswire•last month
The National Comprehensive Cancer Network (NCCN) Guidelines Recommend BRAFTOVI™ (encorafenib) in Combination with MEKTOVI® (binimetinib) as a Category 1 Treatment Option for Patients with Advanced BRAF-mutant Melanoma
BOULDER, Colo. , July 13, 2018 /PRNewswire/ -- Array BioPharma Inc. (NASDAQ: ARRY) today announced that the National Comprehensive Cancer Network (NCCN) has updated the Clinical Practice Guidelines in ...
- Market Realist•2 months ago
Array Biopharma Fell, FDA Approval for Melanoma Drug Yesterday
Yesterday, Array Biopharma announced that it received FDA approval for its combination therapy for advanced melanoma associated with a common gene mutation called a BRAF mutation. This is the first marketable regimen for Array Biopharma and is labeled as the first-line therapy.
- Benzinga•2 months ago
Piper Jaffray, Stifel Defend Array Biopharma As Stock Falls On Profit-Taking
The Food and Drug Administration approved Array Biopharma Inc (NASDAQ: ARRY )’s combination therapy of Mektovi and Braftovi in the treatment of BRAF-mutant melanoma on Wednesday. The stock, which rallied ...
- ACCESSWIRE•2 months ago
Today's Research Reports on Trending Tickers: Heron Therapeutics and Array BioPharma
NEW YORK, NY / ACCESSWIRE / June 28, 2018 / U.S. equities fell sharply on Wednesday, weighed by losses from the consumer staples and technology sectors. The Dow Jones Industrial Average decreased 0.68 ...
- Reuters•2 months ago
Array BioPharma gets FDA nod for melanoma combo treatment
The U.S. Food and Drug Administration said on Wednesday it approved Array BioPharma Inc's oral combination treatment for use in patients with the deadliest form of skin cancer. The combination therapy, which consists of encorafenib and binimetinib, was approved based on the company's late-stage trial, whose results were released earlier this month. It showed that half the patients treated with the combination survived advanced melanoma with a common gene mutation called a BRAF mutation nearly three years after the treatment.
- Benzinga•2 months ago
Array BioPharma Touts Approval Of Melanoma Drug
Array Biopharma Inc (NASDAQ: ARRY ) shares were halted Wednesday after the Food and Drug Administration approved its drug candidate. What Happened The FDA approved Braftovi in combination with Mektovi ...
